Table S4 Information of breast cancer patients in clinic

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No** |  **Age** | **Subtypes** | **Histological****Grade** | **Chemotherapy** |  **Response** |
| 1 | 55 | Luminal A | II | paclitaxel | CR |
| 2 | 46 | Luminal A | III | paclitaxel | CR |
| 3 | 48 | Luminal A | II-III | paclitaxel | CR |
| 4 | 46 | Luminal A | II | paclitaxel | CR |
| 5 | 39 | Luminal A | II-III | paclitaxel | CR |
| 6 | 61 | Luminal A | III | paclitaxel | CR |
| 7 | 39 | Luminal A | III | paclitaxel | CR |
| 8 | 57 | Luminal A | II | paclitaxel | CR |
| 9 | 41 | Luminal A | III | paclitaxel | CR |
| 10 | 67 | Luminal A | II | paclitaxel | CR |
| 11 | 43 | Luminal A | III | paclitaxel | CR |
| 12 | 49 | Luminal A | III | paclitaxel | CR |
| 13 | 59 | Luminal B | II | paclitaxel | CR |
| 14 | 62 | Luminal B | III | paclitaxel | PR |
| 15 | 68 | Luminal B | II-III | paclitaxel | PR |
| 16 | 55 | Luminal B | II | paclitaxel | CR |
| 17 | 65 | Luminal B | III | paclitaxel | PR |
| 18 | 64 | Luminal B | II-III | paclitaxel | PR |
| 19 | 59 | Luminal B | II | paclitaxel | CR |
| 20 | 69 | Luminal B | III | paclitaxel | PR |
| 21 | 63 | Luminal A | II-III | paclitaxel | SD |
| 22 | 53 | Luminal A | II | paclitaxel | SD |
| 23 | 48 | Luminal A | III | paclitaxel | SD |
| 24 | 43 | Luminal A | III | paclitaxel | SD |
| 25 | 46 | Luminal A | III | paclitaxel | SD |
| 26626 | 57 | Luminal A | II-III | paclitaxel | SD |
| 27 | 51 | Luminal A | II | paclitaxel | SD |
| 28 | 49 | Luminal A | III | paclitaxel | SD |
| 29 | 46 | Luminal A | III | paclitaxel | SD |
| 30 | 31 | Luminal A | III | paclitaxel | SD |
| 31 | 41 | Luminal B | III | paclitaxel | SD |
| 32 | 63 | Luminal B | I | paclitaxel | SD |
| 33 | 48 | Luminal B | III | paclitaxel | SD |
| 34 | 38 | Luminal B | II | paclitaxel | SD |
| 35 | 44 | Luminal B | I | paclitaxel | SD |
| 36 | 41 | Luminal B | III | paclitaxel | PD |
| 37 | 50 | Luminal B | III | paclitaxel | PD |
| 38 | 45 | Luminal B | III | paclitaxel | PD |

Table S4 Information of breast cancer patients in clinic

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No** | **Age** | **Subtypes** | **Histological****Grade** | **Chemotherapy** |  **Response** |
| 39 | 35 | Luminal B | III | paclitaxel | PD |
| 40 | 57 | Luminal B | III | paclitaxel | PD |
| 41 | 39 | TNBC | II | paclitaxel | CR |
| 42 | 63 | TNBC | II | paclitaxel | CR |
| 43 | 67 | TNBC | II | paclitaxel | CR |
| 44 | 72 | TNBC | II | paclitaxel | CR |
| 45 | 55 | TNBC | III | paclitaxel | CR |
| 46 | 58 | TNBC | II | paclitaxel | CR |
| 47 | 57 | TNBC | II | paclitaxel | CR |
| 48 | 52 | TNBC | I | paclitaxel | CR |
| 49 | 65 | TNBC | II | paclitaxel | CR |
| 50 | 59 | TNBC | I | paclitaxel | CR |
| 51 | 60 | TNBC | II | paclitaxel | CR |
| 52 | 52 | TNBC | III | paclitaxel | CR |
| 53 | 69 | TNBC | III | paclitaxel | CR |
| 54 | 76 | TNBC | I-II | paclitaxel | CR |
| 55 | 65 | TNBC | III | paclitaxel | CR |
| 56 | 47 | TNBC | II | paclitaxel | CR |
| 57 | 56 | TNBC | I-II | paclitaxel | CR |
| 58 | 62 | TNBC | II-III | paclitaxel | CR |
| 59 | 42 | TNBC | II-III | paclitaxel | CR |
| 60 | 58 | TNBC | III | paclitaxel | CR |
| 61 | 59 | TNBC | II | paclitaxel | PR |
| 62 | 47 | TNBC | II | paclitaxel | PR |
| 63 | 65 | TNBC | II | paclitaxel | PR |
| 64 | 68 | TNBC | II | paclitaxel | PR |
| 65 | 69 | TNBC | III | paclitaxel | PR |
| 66 | 68 | TNBC | II | paclitaxel | SD |
| 67 | 57 | TNBC | III | paclitaxel | SD |
| 68 | 57 | TNBC | II | paclitaxel | SD |
| 69 | 54 | TNBC | II | paclitaxel | SD |
| 70 | 48 | TNBC | III | paclitaxel | SD |
| 71 | 47 | TNBC | II | paclitaxel | SD |
| 72 | 80 | TNBC | II | paclitaxel | SD |
| 73 | 81 | TNBC | II | paclitaxel | SD |
| 74 | 67 | TNBC | III | paclitaxel | SD |
| 75 | 61 | TNBC | III | paclitaxel | SD |
| 76 | 59 | TNBC | III | paclitaxel | SD |

Table S4 Information of breast cancer patients in clinic

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No** | **Age** | **Subtypes** | **Histological****Grade** | **Chemotherapy** |  **Response** |
| 77 | 32 | Luminal B | II | paclitaxel | SD |
| 78 | 42 | Luminal B | II | paclitaxel | SD |
| 79 | 37 | TNBC | II | paclitaxel | SD |
| 80 | 45 | TNBC | II | paclitaxel |

|  |
| --- |
| SD |
|  SD |
| SD |

YES |
| 81 | 40 | TNBC | II | paclitaxel |

|  |
| --- |
| SD |
|  SD |
| SD |

YES |
| 82 | 57 | TNBC | II | paclitaxel |

|  |
| --- |
| SD |
| SD |
| SD |

YES |
| 83 | 57 | TNBC | III | paclitaxel | PD |
| 84 | 51 | TNBC | II | paclitaxel | PD |
| 85 | 59 | TNBC | II | paclitaxel | PD |
| 86 | 52 | TNBC | I | paclitaxel | PD |
| 87 | 63 | TNBC | II | paclitaxel | PD |
| 88 | 58 | TNBC | I | paclitaxel | PD |
| 89 | 60 | TNBC | II | paclitaxel | PD |
| 90 | 62 | TNBC | II | paclitaxel | PD |

All information was collected in Breast Center, the First Affiliated Hospital, College of Medicine, Zhejiang University. This study was approved by the Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.

CR, Complete Response.

PR, Partial Response.

SD, Stable Disease.

PD, Progressive Disease.